[go: up one dir, main page]

DE69635907D1 - Neuartige nicht pyrogene bakterienstämme und ihre verwendung - Google Patents

Neuartige nicht pyrogene bakterienstämme und ihre verwendung

Info

Publication number
DE69635907D1
DE69635907D1 DE69635907T DE69635907T DE69635907D1 DE 69635907 D1 DE69635907 D1 DE 69635907D1 DE 69635907 T DE69635907 T DE 69635907T DE 69635907 T DE69635907 T DE 69635907T DE 69635907 D1 DE69635907 D1 DE 69635907D1
Authority
DE
Germany
Prior art keywords
pyrogenic
strains
present
preparation
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635907T
Other languages
English (en)
Inventor
David M Hone
Robert J Powell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69635907D1 publication Critical patent/DE69635907D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69635907T 1995-11-22 1996-11-22 Neuartige nicht pyrogene bakterienstämme und ihre verwendung Expired - Lifetime DE69635907D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US747895P 1995-11-22 1995-11-22
PCT/US1996/019875 WO1997018837A1 (en) 1995-11-22 1996-11-22 Novel non-pyrogenic bacterial strains and use of the same

Publications (1)

Publication Number Publication Date
DE69635907D1 true DE69635907D1 (de) 2006-05-04

Family

ID=21726420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635907T Expired - Lifetime DE69635907D1 (de) 1995-11-22 1996-11-22 Neuartige nicht pyrogene bakterienstämme und ihre verwendung

Country Status (6)

Country Link
US (2) US5997881A (de)
EP (1) EP0841941B1 (de)
AT (1) ATE319476T1 (de)
AU (1) AU2278497A (de)
DE (1) DE69635907D1 (de)
WO (1) WO1997018837A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP1012232B1 (de) * 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US6316231B1 (en) * 1998-09-11 2001-11-13 Archer-Daniels-Midland Company Bacterial strains for the production of 2-keto-L-gulonic acid
DE19844191A1 (de) * 1998-09-28 2000-03-30 Pharma Zentrale Gmbh Lipopolysaccharide aus Escherichia coli
AU1431101A (en) * 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
EP1414499A2 (de) * 1999-10-04 2004-05-06 Vion Pharmaceuticals, Inc. Nicht invasives tumor-imaging mittels tumorgerichteter bakterien
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
ATE534402T1 (de) 2000-06-29 2011-12-15 Smithkline Beecham Biolog Multivalente impfstoffzusammensetzung
JP2004510746A (ja) * 2000-10-06 2004-04-08 パラディース，ハー．，ヘンリッヒ 免疫調節効果を有する自家ワクチンとしてのカイバードラッグ
EP1345621B1 (de) 2000-11-16 2008-11-12 Intervet International BV Salmonella vakzine
US7015027B1 (en) 2001-11-20 2006-03-21 Mds (Canada) Inc. Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria
JP4617449B2 (ja) 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
US20040075039A1 (en) * 2002-08-16 2004-04-22 Dubey Dharmesh K. Molds for producing contact lenses
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
WO2006015445A1 (en) 2004-08-13 2006-02-16 Marshall Barry J Bacterial delivery system
CA2585098C (en) 2004-10-22 2018-12-18 Revivicor, Inc. Porcine genomic kappa and lambda light chain sequences
US7766900B2 (en) 2005-02-21 2010-08-03 Biomet Manufacturing Corp. Method and apparatus for application of a fluid
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
JP5820564B2 (ja) * 2006-05-24 2015-11-24 スカラブ ゲノミクス， エルエルシー プラスミドｄｎａ調製物およびそれらの作製方法
US8795680B2 (en) * 2006-07-21 2014-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-D-manno-octulsonic acid
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8518272B2 (en) 2008-04-04 2013-08-27 Biomet Biologics, Llc Sterile blood separating system
US8182769B2 (en) 2008-04-04 2012-05-22 Biomet Biologics, Llc Clean transportation system
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
EP2348827B1 (de) 2008-10-27 2015-07-01 Revivicor, Inc. Immunsupprimierte huftiere
DK2349520T3 (en) * 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
PH12012500477A1 (en) 2009-09-10 2012-10-22 Merial Inc New vaccine formulations comprising saponin-containing adjuvants
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
AU2011215616A1 (en) * 2010-02-15 2012-09-06 Transition Therapeutics Ireland Limited Process for the preparation of scyllo-Inositol
WO2012051395A1 (en) 2010-10-13 2012-04-19 Elan Pharmaceuticals, Inc. Methods of synthesis of scyllitol and related compounds
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
AU2012278407B2 (en) 2011-07-07 2017-01-19 Intravacc B.V. A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
WO2013128288A1 (en) 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
MX368210B (es) 2013-01-02 2019-09-24 Decoy Biosystems Inc Composiciones que comprenden bacterias y usos de las mismas en el tratamiento del cáncer.
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014138696A1 (en) 2013-03-07 2014-09-12 University Of Maryland, Baltimore Immunotherapeutic potential of modified lipooligosaccharides/lipid a
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10206614B2 (en) 2015-01-20 2019-02-19 Paw Bioscience Products, Llc Pre-sterilized syringe system and method of use
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2018007814A (es) 2015-12-22 2018-08-15 Glaxosmithkline Biologicals Sa Procedimiento de extraccion de lipopolisacaridos.
EP3263695A1 (de) 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogene zusammensetzungen
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
MX2021000165A (es) 2018-07-11 2021-05-28 Actym Therapeutics Inc Cepas bacterianas inmunoestimuladoras modificadas y usos de las mismas.
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP7570321B2 (ja) 2018-09-27 2024-10-21 デコイ バイオシステムズ インコーポレイテッド 細菌を用いる感染症治療の方法
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP4277654A1 (de) 2021-01-18 2023-11-22 Conserv Bioscience Limited Immunogene coronavirus-zusammensetzungen, verfahren und verwendungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595660A (en) * 1983-03-02 1986-06-17 University Of Delaware Molecular cloning with bifunctional plasmid vectors in Bacillus subtilis, mutants and substantially stably transformed mutants of Bacillus subtilis, and methods for utilizing the transformed mutants
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence

Also Published As

Publication number Publication date
EP0841941A4 (de) 2001-11-14
AU2278497A (en) 1997-06-11
US6548287B1 (en) 2003-04-15
US5997881A (en) 1999-12-07
EP0841941A1 (de) 1998-05-20
WO1997018837A1 (en) 1997-05-29
ATE319476T1 (de) 2006-03-15
EP0841941B1 (de) 2006-03-08

Similar Documents

Publication Publication Date Title
DE69635907D1 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
EA200000130A1 (ru) Клеточная везикула, называемая "экзосома", ее получение и применение для стимуляции иммунного ответа
HUP9900920A2 (hu) Eljárás emlőssejt-tenyészetekben termelt proteinek szializációjának szabályozására
Neeser et al. In vitro modulation of oral bacterial adhesion to saliva‐coated hydroxyapatite beads by milk casein derivatives
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
Huebner et al. Production of type-specific C antigen in virus-free hamster tumor cells induced by adenovirus type 12
DE69637942D1 (de) Stimulationsfaktor für dendriten
BR9811675A (pt) Genes isolados para proteìna da membrana de célula dentrìtica
DK0480949T4 (da) Fremstilling af virusvaccine
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
ATE159170T1 (de) Impfstoffe und diagnosetest für haemophilus influenzae
BR0016212A (pt) Proteìna especìfica do cromossoma sexual e sequência de ácido nucleico isolada e purificada, método para identificar moléculas especìficas de cromossomas sexuais associadas com membranas celulares de esperma animal, anticorpo contra um epìtopo de uma molécula especìfica de cromossomas sexuais, métodos de triagem para uma molécula especifica de cromossomas sexuais, e para separar esperma determinante de macho e fêmea de sêmen nativo kit para executar um método, contraceptivo, proteìna especìfica do cromossoma sexual isolada e purificada, e , molécula
DE68923286D1 (de) Impfstoffe und testsätze für haemophilus influenzae.
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
AU5573196A (en) A pluripotent vaccine against enveloped viruses
ATE160376T1 (de) Dna segment des herpesvirus der marek-krankheit, welches für das glykoprotein ge kodiert
Sledge et al. Costae of Tritrichomonas foetus: purification and chemical composition
AU2001249649A1 (en) 16836, a novel human phospholipase c family member and uses thereof
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
CA2158461A1 (en) Stimulation of immune response by viral protein
Hale et al. Elicitation of anti-viral cytotoxic T lymphocytes with purified viral and H-2 antigens.
BR9814556A (pt) Cepas isoladas de staphylococcus aureus e vacinas fabricadas a partir das mesmas
DE60137222D1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc-2
Saunders et al. Humoral response of the mouse to Treponema pallidum.
Russell-Jones et al. Peptide sequences with strong stimulatory activity for lymphoid cells: implications for vaccine development

Legal Events

Date Code Title Description
8332 No legal effect for de